본문으로 건너뛰기
← 뒤로

Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors.

Clinical nutrition ESPEN 2026 p. 103288

Wei L, Tian M, Han Q, Wang W, Jin X, Xu X

📝 환자 설명용 한 줄

[BACKGROUND] &Aims: To explore the value of pretreatment myosteatosis and albumin-myosteatosis gauge (AMG) in predicting overall survival (OS) in patients with lung cancer treated with immune checkpoi

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.003
  • p-value p < 0.05
  • 95% CI 0.77-2.76
  • HR 1.46

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Wei L, Tian M, et al. (2026). Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors.. Clinical nutrition ESPEN, 103288. https://doi.org/10.1016/j.clnesp.2026.103288
MLA Wei L, et al.. "Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors.." Clinical nutrition ESPEN, 2026, pp. 103288.
PMID 41974370

Abstract

[BACKGROUND] &Aims: To explore the value of pretreatment myosteatosis and albumin-myosteatosis gauge (AMG) in predicting overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs).

[METHODS] This single-center, retrospective study included a total of 119 patients with lung cancer. Myosteatosis was accessed on pretreatment CT at L3 level by mean skeletal muscle density (SMD). AMG was calculated as SMD * serum albumin. The time-dependent receiver operating characteristic curve was used to determine the optimal AMG score cut-off value. The predictive value of myosteatosis and AMG on overall survival were evaluated by the Kaplan-Meier method and Cox proportional hazard models. A nomogram was created based on AMG to predict OS.

[RESULTS] Patients with low AMG had shorter OS compared with patients with high AMG. (3-year survival rate: low AMG, 20.8% [95%CI: 8.4%-51.9%] versus high AMG, 68.2% [95%CI: 52.4%-88.7%]) No significate difference was observed in patients with and without myosteatosis. (HR= 1.46, 95%CI 0.77-2.76, P=0.246) In the multivariable analysis, AMG remained a significant predictor of OS. (HR = 3.29, 95% CI 1.51-7.16, p = 0.003) The prediction model for OS based on the AMG was also created with C-index 0.78. A statistically significant but weak positive correlation was observed between myosteatosis and sarcopenia (Phi coefficient = 0.24, p < 0.05).

[CONCLUSION] AMG was a significant prognostic factor of OS in patients with lung cancer treated with ICIs. A weak correlation between mysteotosis and sarcopenia was observed in patients with lung cancer.

같은 제1저자의 인용 많은 논문 (5)